Journal of General Virology, Vol 79, 489-499, Copyright © 1998 by Society for General Microbiology

ARTICLES

Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells

PR Daniels, CM Sanders and NJ Maitland
Department of Biology, University of York, UK.

Human papillomavirus (HPV) 16 E6 induces the degradation of the tumour suppressor protein p53 by the ubiquitin-dependent proteolysis pathway. In vitro, this process involves the formation of a trimolecular complex between E6, p53 and a cellular protein E6-associated protein (E6-AP). However, an analysis of their potential interactions in vivo has not been carried out. We have established a model for the expression and analysis of the interactions of these three proteins in insect cells, a eukaryotic system where potentially crucial modifications of the proteins will occur. In baculovirus-infected cells the degradation of p53 can occur. However, p53 is only degraded early in the infectious cycle due to a lack of ATP at later times. Consequently, substantial quantities of material can be produced in this system for further analysis. Evidence is also provided that, in vivo, E6 can interact with p53 in the absence of E6-AP and that E6-AP can interact with p53 in the absence of E6. Furthermore, analysis of the subcellular localization of the proteins using both biochemical fractionation and indirect immunofluorescence suggests that the degradation of p53 occurs in the perinuclear region of the cell.

This article has been cited by other articles:

				S. S. Tungteakkhun, M. Filippova, J. W. Neidigh, N. Fodor, and P. J. Duerksen-Hughes The Interaction between Human Papillomavirus Type 16 and FADD Is Mediated by a Novel E6 Binding Domain J. Virol., October 1, 2008; 82(19): 9600 - 9614. [Abstract] [Full Text] [PDF]

				J. Courtete, A.-P. Sibler, G. Zeder-Lutz, D. Dalkara, M. Oulad-Abdelghani, G. Zuber, and E. Weiss Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA Mol. Cancer Ther., June 1, 2007; 6(6): 1728 - 1735. [Abstract] [Full Text] [PDF]

				M. Masson, C. Hindelang, A.-P. Sibler, G. Schwalbach, G. Trave, and E. Weiss Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells J. Gen. Virol., August 1, 2003; 84(8): 2099 - 2104. [Abstract] [Full Text] [PDF]

				L. G. Le Roux and J. Moroianu Nuclear Entry of High-Risk Human Papillomavirus Type 16 E6 Oncoprotein Occurs via Several Pathways J. Virol., February 15, 2003; 77(4): 2330 - 2337. [Abstract] [Full Text] [PDF]

				C. L. Smith, D. G. DeVera, D. J. Lamb, Z. Nawaz, Y.-H. Jiang, A. L. Beaudet, and B. W. O'Malley Genetic Ablation of the Steroid Receptor Coactivator-Ubiquitin Ligase, E6-AP, Results in Tissue-Selective Steroid Hormone Resistance and Defects in Reproduction Mol. Cell. Biol., January 15, 2002; 22(2): 525 - 535. [Abstract] [Full Text] [PDF]

				S. Hietanen, S. Lain, E. Krausz, C. Blattner, and D. P. Lane Activation of p53 in cervical carcinoma cells by small molecules PNAS, July 18, 2000; 97(15): 8501 - 8506. [Abstract] [Full Text] [PDF]

				D. H. Dreyfus, M. Nagasawa, C. A. Kelleher, and E. W. Gelfand Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells Blood, July 15, 2000; 96(2): 625 - 634. [Abstract] [Full Text] [PDF]

				Y. Liu, J. J. Chen, Q. Gao, S. Dalal, Y. Hong, C. P. Mansur, V. Band, and E. J. Androphy Multiple Functions of Human Papillomavirus Type 16 E6 Contribute to the Immortalization of Mammary Epithelial Cells J. Virol., September 1, 1999; 73(9): 7297 - 7307. [Abstract] [Full Text]

				Z. Nawaz, D. M. Lonard, C. L. Smith, E. Lev-Lehman, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily Mol. Cell. Biol., February 1, 1999; 19(2): 1182 - 1189. [Abstract] [Full Text] [PDF]